We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Nasal Test Developed to Diagnose Creutzfeldt-Jakob Disease

By LabMedica International staff writers
Posted on 19 Aug 2014
A nasal brush test has been developed that can rapidly and accurately diagnose Creutzfeldt-Jakob disease (CJD), an incurable and ultimately fatal neurodegenerative disorder.

Definite diagnosis of sporadic CJD in living patients remains a challenge as up to now, a definitive CJD diagnosis requires testing brain tissue obtained after death or by biopsy in living patients.

An international team of scientists led by those at the National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) studied 31 nasal samples from patients with CJD and 43 nasal samples from patients who had other neurologic diseases or no neurologic disease at all. More...
They obtained olfactory mucosa samples by using a nasal tampon, a rigid fiberoptic rhinoscope, enveloped with a disposable sheath, the Slide-On EndoSheath System (Medtronic Xomed; Minneapolis, MN, USA) and a sterile, disposable brush was then inserted alongside the fibroscope, gently rolled on the mucosal surface and withdrawn, and processed.

An in vitro PrPCJD amplification technology, designated real-time quaking-induced conversion (RT-QuIC), has been shown to have considerable promise as a highly specific diagnostic test for sporadic Creutzfeldt–Jakob disease. Testing with RT-QuIC correctly identified 30 of the 31 CJD patients (97% sensitivity) and correctly showed negative results for all 43 of the non-CJD patients (100% specificity). By comparison, tests using cerebral spinal fluid which is currently used to detect sporadic CJD were 77% sensitive and 100% specific, and the results took twice as long to obtain.

Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, said, “This exciting advance, the culmination of decades of studies on prion diseases, markedly improves on available diagnostic tests for CJD that are less reliable, more difficult for patients to tolerate, and require more time to obtain results. With additional validation, this test has potential for use in clinical and agricultural settings.” The study was published on August 7, 2014, in the New England Journal of Medicine (NEJM).

Related Links:

US National Institute of Allergy and Infectious Diseases
Medtronic Xomed



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Hematology Analyzer
Medonic M32B
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.